FDA-approved options for chronic weight management include: Other GLP-1 receptor agonists (semaglutide, liraglutide) Combination therapies (phentermine-topiramate ER, naltrexone-bupropion ER) Orlistat Metformin for patients with diabetes or prediabetes, which provides modest weight-neutral or weight-loss effects Realistic expectations are essential
FDA regulates the manufacturing of mass-manufactured drugs, including brand-name semaglutide drugs
Resistance training is critical with both compounds to preserve lean mass, but the specifics may differ
[12] [13] While these mechanisms contribute to improved glycemic control and weight loss, they also explain why gastrointestinal side effects are among the most commonly reported adverse reactions
Tirzepatide (Mounjaro) , a dual GIP/GLP-1 receptor agonist, has been under NICE appraisal for weight management
The trade-off is age: it launched in June 2025, so theres no Trustpilot or BBB track record yet